TRxADE HEALTH Inc
TRxADE HEALTH Inc (MEDS) is a health service IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey, and patient engagement in the U.S.. The firm operates the TRxADE drug procurement marketplace serving a total of 12,100+ members nationwide, fostering price transparency.
Under the Bonum Health brand, the firm offers patient-centric telehealth services.
For more information, please visit the Company’s IR website by clicking here.
TRxADE HEALTH NEWS
TRxADE HEALTH announced that its subsidiary, Bonum Health Digital Healthcare business, has signed a Telemedicine Service Distribution Deal with Big Y Pharmacy and Wellness Centers within their supermarkets in Massachusetts and Connecticut.
Bonum Health will provide affordable telemedicine services to the patients of all Big Y pharmacies by offering Bonum Health’s signature Mobile Health Services and prescriber program, staffed by over 600 board-certified medical providers. The partnership also provides Big Y patients direct access to prescription discount savings through Bonum Health. The gap between uninsured and under-insured consumers across Massachusetts and Connecticut widens daily, and consumers are demanding easier access to affordable healthcare providers.
From the Director of Center Store and Pharmacy
Steve Nordstrom, Director of Center Store and Pharmacy, stated, “Big Y wanted to expand our digital healthcare offerings and to enhance our collaborative care network. Bonum Health is a strategic partner that helps us diversify our in-store and community digital healthcare services. Their mobile application enables a turn-key Telemedicine and Prescriptions Savings tool to seamlessly integrate into our Big Y pharmacies.”
About Big Y Foods, Inc.
Big Y Foods, Inc. is one of the largest independently-owned supermarket chains in New England. Big Y operates 84 locations throughout Massachusetts and Connecticut including 71 supermarkets, Fresh Acres Market, Table & Vine Fine Wines and Liquors, and 10 Big Y Express gas and convenience locations with almost 12,000 employees.
Big Y has been recognized by Forbes as a Best-in-State Employer in Massachusetts and Connecticut, as well as Employer of Choice by the Employers Association of the Northeast. Founded in 1936 by brothers Paul and Gerald D’Amour, the store was named after an intersection in Chicopee, Massachusetts where two roads converge to form a “Y”.
TRxADE HEALTH is not a biotech or pharmaceutical company, as it does not design and develop drugs. To know the value of this firm’s expertise read the comments written by Ashton Maaraba, the President of Bonum Health who said, “We are thrilled and fortunate to team up with Big Y and their outstanding Health & Wellness leadership and in-store staff. Big Y pharmacy leadership recognized an opportunity to provide greater access to deeply discounted low-cost care to their patients, in combination with furthering their prescription discounts, under our unique digital platform, and Big Y chose Bonum Health. We are looking forward to serving each Big Y consumer household.”
The firm’s stock rocketed in the early morning on Tuesday. As of mid-day today the stock is trading at $7.49, UP $3.07.
We will definitely follow up on this firm’s activities.
A week ago, Innate Pharma SA (IPHA) announced preliminary data from the mycosis fungoides (MF) cohort of Phase 2 TELLOMAK clinical trial which evaluated the firm’s product lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody.
The announcement was made in an oral presentation at the 16th International Conference on Malignant Lymphoma (16-ICML).
The news acknowledged that lacutamab demonstrated clinical responses in patients with MF that express KIR3DL2, reaching the pre-determined threshold to advance to stage 2.
According to the firm’s press release, as of May 10, 2021 data cutoff, in the KIR3DL2-expressing cohort complete, partial and unconfirmed partial global responses were observed.
Following the data cutoff, the two unconfirmed partial responses have been confirmed.
When evaluating responses in the skin, one patient had a complete response, eight patients had a partial response and two patients had an unconfirmed partial response.
Out of seven patients with blood involvement, four had a complete response in the blood, and out of eight patients with lymph node involvement, one had a partial response.
Following the data cutoff, unconfirmed partial responses in the skin have been confirmed.
All patients in the KIR3DL2-non-expressing cohort (Cohort 3) have been recruited. The threshold of responses needed to advance to stage 2 has not been reached, and the follow-up is ongoing.
From the CMO at Innate Pharma
Joyson Karakunnel, M.D., MSc, FACP, Chief Medical Officer of Innate Pharma, said, “We are pleased by the response demonstrated to date in patients with mycosis fungoides that express KIR3DL2, which has enabled us to advance this cohort earlier than expected. These data confirm our initial hypothesis that lacutamab may benefit patients with KIR3DL2-expressing T-cell lymphomas, and support our data-driven approach in pursuit of a new standard of care in this population. Looking ahead, we continue to enroll patients in both the mycosis fungoides and Sézary syndrome cohorts of our TELLOMAK study. In addition, we plan to initiate our peripheral T-cell lymphoma program for lacutamab, with our Phase 1b monotherapy study expected to start mid-year and an investigator-sponsored combination study expected in the second half of this year.”
In line with previous observations, lacutamab demonstrated a favorable safety profile in MF. Grades 1-2 treatment-related adverse events (AE) were observed, with one patient (out of 36) experiencing a grade 3 AE. No relevant skin toxicities were observed.
From St. Louis Hospital, Paris
Pr. Martine Bagot, Head of the Dermatology Department, Saint Louis Hospital, Paris, and a study investigator said, “Mycosis fungoides, and cutaneous T-cell lymphomas more broadly, are associated with poor clinical outcomes, particularly at advanced stages. The clinical responses and favorable safety profile observed in the TELLOMAK study are quite encouraging so far. I am particularly pleased by the preliminary skin responses, as relapsed/refractory patients are in need for new treatment options that can improve their quality of life, and slow disease progression. I look forward to seeing more data from lacutamab as this trial progresses with the enrollment of additional patients in this cohort.”
IPH4102 is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for cutaneous T-cell lymphoma (CTCL).
This group of rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few efficacious and safe therapeutic options at advanced stages.
Lacutamab targets KIR3DL2 – an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up 90% of patients with certain aggressive CTCL subtypes, in particular, Sézary syndrome.
It is expressed by up to 50% of patients with mycosis fungoides and peripheral T-cell lymphoma (PTCL). It has a restricted expression on normal tissues.
The TELLOMAK trial is a global, open-label, multi-cohort Phase 2 clinical trial recruiting patients with Sézary syndrome and MF in the United States and Europe.
Cohort 1: lacutamab being evaluated as a single agent in approximately 60 patients with Sézary syndrome who have received at least two prior systemic therapies, including mogamulizumab.
Cohort 2: lacutamab being evaluated as a single agent in up to approximately 50 patients with MF that express KIR3DL2, as determined at baseline.
Cohort 3: lacutamab being evaluated as a single agent in up to approximately 38 patients with MF that do not express KIR3DL2, as determined at baseline.
The MF cohorts follow a Simon 2-stage design that will terminate early if treatment is considered futile.
The Sézary syndrome cohort of the study could enable the registration of lacutamab in this indication.
The primary endpoint of the trial is the objective global response rate. Key secondary endpoints are progression-free survival, duration of response, quality of life and adverse events.
Global response in cutaneous lymphoma is measured by the guidelines published by Olsen et. al in the Journal of Clinical Oncology in 2011.
Innate Pharma is a small firm with a stock now selling at $3.45. The Market CAP. is only $218 Million.
Regardless of the firm’s small size, history and small Market CAP, we like its latest news.
We will keep our eyes on this firm’s next steps, knowing, in fact, that its product is still in the early stage and therefore may take time for its stock to rally.
Please visit our website for other news.